CA-BELKIN
4.1.2023 15:01:52 CET | Business Wire | Press release
Belkin, a global consumer electronics leader, after two years of development, today introduces a new product material refresh for its top selling mobile power products. Several of Belkin’s most popular wireless chargers, power banks, wall chargers, and car chargers will receive updated product housing materials that consist of 73-75% post-consumer recycled plastics (PCR) and plastic-free packaging. The product transition will be rolled out beginning 2023 and will save an estimated 7,000 metric tons of carbon emissions1 and reduce CO2-eq emissions for these products by up to 67%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005370/en/
(Photo: Business Wire)
The company celebrates 40 years as a market leader and innovator by honoring its deeply rooted commitment to sustainability. Belkin is already on its way to becoming 100% carbon neutral in scope 1 & 2 emissions by 2025. Its commitment to reviewing all areas of the business has included a focus on reducing single-use plastics in packaging which has seen up to a 90% reduction in plastic usage in some products. Today’s announcement addresses Belkin’s approach to reducing its scope 3 emissions.
Belkin made a deliberate and methodical decision to transition product materials to PCR. This takes plastic waste from consumers and repurposes it to create new products. It utilizes plastic that is destined for landfill, giving it new life, while taking meaningful steps to support the circular economy by reducing dependence on virgin plastics. The Life Cycle Assessment conducted by the company shows that utilizing PCR material has a significant reduction in environmental impact.
There are other plastic alternatives in the industry such as:
- Recycled plastic (PIR), a method that reuses plastic materials collected at a factory during mass production
- Bioplastics, which uses materials from renewable feedstocks such as plants and woodchips
- Ocean plastics, which reuses plastic waste collected from the ocean
“When we think about the difference a company of our size and influence can make on the planet, moving away from using virgin plastics in our products is an obvious decision,” said Steve Malony, CEO, Belkin. “I am proud to work alongside the teams that made this shared vision a reality. Their dedication to doing the right thing inspires me and together, we will continue to work towards a more sustainable future.”
The following products will be the first to ship with the new PCR material throughout 2023:
- BOOST↑CHARGE™ Magnetic Wireless Car Charger 10W
- BOOST↑CHARGE™ USB-C PD 3.0 PPS Wall Charger 25W
- BOOST↑CHARGE™ Dual USB-C PD Wall Charger 40W
- BOOST↑CHARGE™ PRO 4-Port GaN Charger 108W
- BOOST↑CHARGE™ PRO Dual USB-C® GaN Wall Charger with PPS 45W
- BOOST↑CHARGE™ PRO Dual USB-C® GaN Wall Charger with PPS 65W
From an aesthetic, quality and engineering perspective, there will be little difference between existing Belkin products and Belkin PCR products. Consumers will be able to decipher the new PCR products by clear callouts on the packaging and product pages online such as: “Made with Recycled Plastic Products” and “100% Plastic Free Packaging.”
Belkin’s engineering and product development teams are based in Los Angeles, Hong Kong, Shenzhen, Vietnam and Taiwan, and work tirelessly to develop innovation that changes the way people connect with their technology while reducing impact on the planet. Belkin takes quality seriously, and nothing enters the market until rigorous testing and approval processes take place. For this new PCR portfolio, Belkin additionally continues to explore new solutions and to conscientiously verify the science behind how Belkin can further reduce its impact on the planet while not compromising on quality. PCR material was sourced from reputable resin vendors and selected and tested by Belkin’s design assurance team.
To learn more about Belkin Sustainability, visit: https://www.belkin.com/company/sustainability/
Press kit can be found here.
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people to get more life out of every single day whether at home, at work or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remain forever inspired by people and the planet we live on.
1 Based on forecasted calculations from May 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
